The BIOMEDE study shows the importance of sequencing children brain tumor at diagnosis.

Presented for the first time in November 2019 in the United States, the first results of the major BIOMEDE study, that we have cofunded giving 1.375.000€ to it, will transform how we care about glioma, introducing biopsy at diagnosis as a standard. The benefit for children is double : confirming the exact diagnosis and defining the different biology profiles for this disease in order to guide the choice of treatments.  

Download the press release published on the 3rd of December from Gustave Roussy.